• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, ASHITAKA CAPIOX FX OXYGENATOR OXYGENATOR, CARDIOPULMONARY BYPASS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, ASHITAKA CAPIOX FX OXYGENATOR OXYGENATOR, CARDIOPULMONARY BYPASS Back to Search Results
Catalog Number CX-FX25RWV
Device Problem Coagulation in Device or Device Ingredient (1096)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 11/02/2019
Event Type  malfunction  
Manufacturer Narrative
Udi - not required for product code. Implanted date: device was not implanted. Explanted date: device was not explanted. 510(k): k130520. The actual sample was received for evaluation. Visual inspection revealed that some blood clots had formed around the cardiotomy filter and venous filter. No physical damage, such as a break, was observed in the appearance. The venous filter was removed from the reservoir, and then the venous filter and the defoamer inside it were subjected to visual inspection after submerged in physiological saline solution. No blood clot was found to have formed on the inner surface of the venous filter or on the defoamer. The cardiotomy filter was removed from the reservoir, and then the cardiotomy filter and the defoamer inside it were subjected to visual inspection after submerged in physiological saline solution. Some blood clots were found to have formed on the inner surface of the cardiotomy filter as well as on the inner surface of the defoamer. Visual inspection of the oxygenator sample did not find any anomaly, such as a break, in the appearance; after flushed with physiological saline solution poured by gravity did not find any visible blood clot formation inside it. The inside of the oxygenation module was fixed by being filled with glutaraldehyde-containing saline solution. Then, the housing and the filter were removed and subjected to visual inspection. No visible blood clots were found to have formed on the outer or inner surfaces of the filter. The oxygenation module was visually inspected; no visible blood clots were found to have formed, the state of the fiber winding was confirmed to be normal. The fiber layer was removed from the winding in increments of 2mm and each layer was subjected to visual inspection. No blood clots were found to have formed. The outer cylinder was removed from the heat exchanger module and the inside of the heat exchanger module was subjected to visual and magnifying inspections. No blood clots were found to have formed. Both sides of the filter that had been removed were inspected under magnification. No blood clots were found to have formed. The fiber layers removed from the upper and bottom sides were inspected under magnification. No blood clots were found to have formed. To visualize the flow behavior in the actual reservoir sample, the following test was conducted: physiological saline solution was circulated in a factory-retained sample at the flow rate of 4l/min. With the liquid level in the reservoir kept at 3000ml. During the circulation, 100ml of india ink was poured into the reservoir from one of the ports on the cardiotomy filter, while the flow behavior of the india ink was observed. The india ink was found to stagnate around the venous filter. (*the circulation conditions were set optionally in this test. ) a review of the device history record and product release decision control sheet of the product code/lot# combination was conducted with no findings. Ifu states: do not reduce heparin during circulation. Otherwise, blood clotting might occur. Adequate heparinization of the blood is required to prevent it from clotting in the system. Based on the provided information and investigation results, there is no definitive evidence that this event was related to a device defect or malfunction. It is likely that terumo's reservoir is designed to have the structure that allows the level of blood reserved in it to be kept stable and to be controlled easily; due to such a structure, it may become difficult for blood to be better agitated in the reservoir. Blood in which coagulation factors had been activated was flowed into the reservoir and stagnated on the solution level, leading to the clot formation. However, the exact cause of the reported event cannot be definitively determined based on the available information. (b)(4).
 
Event Description
The user facility reported that during preparation of the capiox device, for weaning the patient from ecc, when they started reducing the blood volume in the reservoir, a large quantity of blood clots were found to have formed on the surface of the venous filter. As the blood volume in the reservoir was being reduced, the blood clots peeled off and fell. Blood clots were found to have formed also in the cardiotomy filter. The oxygenator was not changed out. The procedure was completed successfully, and the patient was not harmed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameCAPIOX FX OXYGENATOR
Type of DeviceOXYGENATOR, CARDIOPULMONARY BYPASS
Manufacturer (Section D)
TERUMO CORPORATION, ASHITAKA
150 maimaigi-cho
fujinomiya city, 418
JA 418
Manufacturer (Section G)
TERUMO CORPORATION, ASHITAKA
reg. no. 9681834
150 maimaigi-cho
fujinomiya city, 418
JA 418
Manufacturer Contact
theresa mussaw
reg. no. 2243441
950 elkton blvd
elkton, MD 21921
8002837866
MDR Report Key9346588
MDR Text Key205522300
Report Number9681834-2019-00200
Device Sequence Number1
Product Code DTZ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K071494
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 11/20/2019
1 Device was Involved in the Event
0 Patients were Involved in the Event:
Date FDA Received11/20/2019
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator
Device Catalogue NumberCX-FX25RWV
Device Lot Number190724
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/05/2019
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received11/02/2019
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured07/24/2019
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

-
-